AbCellera Biologics (ABCL) Stock Price, News & Analysis

Company Overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $2.62 to $2.72
• 50-Day Range: $2.44 to $3.15
• 52-Week Range: $2.34 to $6.05
• Volume: 1.72 million shs
• Average Volume: 1.70 million shs
• Market Capitalization: $788.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.67
• Consensus Rating: Moderate Buy

AbCellera Biologics Stock Analysis - MarketRank™

AbCellera Biologics scored higher than 60% of companies evaluated by MarketBeat, and ranked 457th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

AbCellera Biologics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.59) to ($0.71) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AbCellera Biologics is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AbCellera Biologics is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AbCellera Biologics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.04% of the float of AbCellera Biologics has been sold short.

Short Interest Ratio / Days to Cover

AbCellera Biologics has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in AbCellera Biologics has recently decreased by 4.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AbCellera Biologics does not currently pay a dividend.

Dividend Growth

AbCellera Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.04% of the float of AbCellera Biologics has been sold short.

Short Interest Ratio / Days to Cover

AbCellera Biologics has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in AbCellera Biologics has recently decreased by 4.09%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

AbCellera Biologics has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for AbCellera Biologics this week, compared to 3 articles on an average week.

Search Interest

18 people have searched for ABCL on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AbCellera Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.00% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABCL Stock Analysis - Frequently Asked Questions

How have ABCL shares performed this year?

AbCellera Biologics' stock was trading at $5.71 at the beginning of 2024. Since then, ABCL shares have decreased by 53.2% and is now trading at $2.67.
View the best growth stocks for 2024 here.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) posted its earnings results on Monday, November, 4th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The company earned $6.51 million during the quarter, compared to analysts' expectations of $8.95 million. AbCellera Biologics had a negative net margin of 533.32% and a negative trailing twelve-month return on equity of 15.73%.

When did AbCellera Biologics IPO?

AbCellera Biologics (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

Who are AbCellera Biologics' major shareholders?

Top institutional investors of AbCellera Biologics include Baillie Gifford & Co. (4.38%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.55%), State Street Corp (0.11%) and Walleye Capital LLC (0.09%). Insiders that own company stock include Holdings Ltd Thermopylae, Veronique Lecault, Andrew Booth, Andrew Lo and John S Montalbano.
View institutional ownership trends.

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of AbCellera Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and AUO (AUOTY).

Company Calendar

• Last Earnings: 11/04/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/18/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ABCL
• CUSIP: N/A
• CIK: 1703057
• Web: www.abcellera.com
• Phone: 604-559-9005
• Fax: N/A
• Employees: 586
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.67
• High Stock Price Target: $12.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +224.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-146,400,000.00
• Net Margins: -533.32%
• Pretax Margin: -613.32%
• Return on Equity: -15.73%
• Return on Assets: -12.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.34
• Quick Ratio: 9.34

Sales & Book Value

• Annual Sales: $38.03 million
• Price / Sales: 20.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.97 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 295,370,000
• Free Float: 212,664,000
• Market Cap: $788.64 million
• Optionable: Optionable
• Beta: 0.35